Clinics win battle over meaning of 2016 FOIA amendments
news.cornell.edu
news.cornell.edu
[..] The email posed a simple inquiry – “lawsuit?” – as a possible way to promote transparency for clinical trial data in the wake of multiple scandals involving drugs that turned out to be less safe and effective than suggested by the analysis of the confidential trial data conducted by the pharmaceutical companies themselves.
It beggars belief that any clinical trial data used for FDA approval can remain confidential. That the safety analysis is conducted by the same companies hoping to sell the drugs makes this utterly farcical.
It's good the lawsuit managed to slightly increase transparency, but my God, what a small victory...